Amgen study: Biosimilars saved the healthcare system $21B

Biosimilars saved the healthcare system $21 billion over the past six years, according to a recent Amgen report.

Nearly 40 biosimilars received regulatory approval over that period, with 22 products launched. The report found that these biosimilars have gained a significant market share during that time and argued that the additional competition may lead to meaningful savings for the healthcare industry, leading to more resources allocated for innovative treatments.